Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Valeant Pharma target lowered to $17 at Rodman & Renshaw (13.06)Rodman & Renshaw lowers their VRX tgt to $17 from $23. Last week, Valeant reported its 4Q16 and FY2016 financial results, while also providing financial guidance for 2017. Although Valeant reported 4Q16 revenues that narrowly beat firm's ests, coming in at $2.4B vs. firm's projection of $2.29B, <strong>its guidance for 2017 remains indicative of further attrition in co's base businesses.</strong> They are therefore lowering their 2017 cash EPS est from $4.52 to $4.19, which also reflects the loss of rev and earnings from the sale of certain dermatology brands to L'Oréal and the divestiture of Dendreon to Sanpower Corp. Firm's FY2017 rev est stands at roughly $8.5B. In the wake of the uninspiring guidance and continued evidence that substantial work needs to be done to return Valeant to a growth trajectory, they reiterate Neutral while lowering price target.</td> </tr></table>"